Rain Oncology Inc. (NASDAQ:RAIN ) Q2 2023 Earnings Call Transcript August 10, 2023 5:00 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Nelson Cabatuan - Acting SVP, Finance Robert Doebele - CSO Conference Call Participants Ashiq Mubarack - Citigroup Joe Catanzaro - Piper Sandler Anshul Dhankher - LifeSci Capital Avantika Joshi - Mizuho Securities Mitchell Kapoor - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Rain Oncology Inc. Second Quarter 2023 Earnings Conference Call.
Rain Oncology (NASDAQ: RAIN ) stock is taking a massive beating on Monday after the company revealed its latest clinical trial data. The bad news for investors in RAIN stock is the company's Phase 3 MANTRA trial failed to meet its primary endpoint.
Rain Oncology, Inc. (NASDAQ:RAIN ) Q1 2023 Earnings Conference Call May 11, 2023 5:00 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Robert Doebele - CSO Richard Bryce - CMO Nelson Cabatuan - SVP, Finance Conference Call Participants Yigal Nochomovitz - Citigroup Michael Schmidt - Guggenheim Joe Catanzaro - Piper Sandler Soumit Roy - Jones Trading Sam Slutsky - LifeSci Capital Jeff Jones - Oppenheimer Faisal Khurshid - SVB Securities Mitchell Kapoor - H.C. Wainwright Avantika Joshi - Mizuho Securities Tony Butler - EF Hutton Operator Greetings, and welcome to the Rain Oncology, Inc. First Quarter 2023 Earnings Call.
Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data.
Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023.